Nexus AG develops and sells software solutions for the healthcare market in Germany, Switzerland, Liechtenstein, the Netherlands, Poland, France, Austria, and internationally. The company operates through NEXUS / DE; NEXUS / DIS; and NEXUS / ROE segments. It offers hospitals information systems, mobile solutions, digital charts and medication, PDMS and device connection, care documentation, appointment and resource management, OP management and CSSD, emergency, medical archive and VNA, patient portal, and diagnostics solutions for hospitals and clinics. The company also provides human genetics, molecular pathology, HBOC, specialized laboratories, special diagnostics, gynecological hospital, ophthalmology, advanced reporting, MARIS healthcare GmbH, and ViREQ software solutions GmbH solutions for diagnostics. In addition, it offers radiology and VNA solutions consisting of radiology information system, vendor neutral archive, PACS, teleradiology portal, telemedicine portal, referral portal, patient portal for images and diagnostic findings, webviewer, telemedicine networking, and DICOM RT-viewer; and residential and psychiatry solutions. Further, the company provides pathology, cytology, and laboratory solutions, as well as IT services comprising integrated solutions. NEXUS AG was founded in 1989 and is headquartered in Donaueschingen, Germany. As of January 3, 2025, Nexus AG was taken private.
Research context
Nexus AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Health Information Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 7 months ago
Nexus AG is currently in a long term uptrend where the price is trading 19.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Nexus AG's total revenue rose by 14.5% to $47M since the same quarter in the previous year.
Its net income has increased by 45.3% to $6M since the same quarter in the previous year.
Finally, its free cash flow grew by 178.6% to $3M since the same quarter in the previous year.
Based on the above factors, Nexus AG gets an overall score of 5/5.